Acumen Pharmaceuticals (ABOS) Cash & Equivalents (2020 - 2026)

Acumen Pharmaceuticals (ABOS) has 7 years of Cash & Equivalents data on file, last reported at $51.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 70.43% year-over-year to $51.4 million; the trailing twelve-month figure through Mar 2026 stood at $51.4 million (up 70.43% YoY), and the FY2025 full-year result was $54.0 million, up 52.94% from the prior year.
• Cash & Equivalents fell to $51.4 million in Q1 2026, from $54.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $157.5 million in Q3 2022 to a low of $30.2 million in Q1 2025.
• A 5-year average of $72.1 million and a median of $66.2 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents jumped 201.81% in 2022 and tumbled 65.44% in 2024, its largest moves.
• Tracing ABOS's Cash & Equivalents over 5 years: stood at $130.1 million in 2022, then tumbled by 49.12% to $66.2 million in 2023, then sank by 46.68% to $35.3 million in 2024, then soared by 52.94% to $54.0 million in 2025, then dropped by 4.8% to $51.4 million in 2026.
• Business Quant data shows ABOS's Cash & Equivalents at $51.4 million in Q1 2026, $54.0 million in Q4 2025, and $46.8 million in Q3 2025.